FIGURE 5 from Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non–small Cell Lung Cancers

Signaling patterns in KRASmut NSCLC xenografts after extended treatment with erlotinib and alisertib. Quantification of Western blot images for A549 tumors (A), with summary of analytes for which the result with the erlotinib+alisertib combination but not with any single drug differed significantly from the vehicle-treated control (B); data are presented as mean ± SEM, n = 4–8 mice. In A549, phospho-AURKA activity was determined by an MSD kit and normalized to the protein content; total AURKA was assessed by Western blotting. In H358, both AURKA forms were measured by Western blotting. Results as for A and B, but showing quantified data (C) and summary analysis (D) for H358 tumors. Primary Western blot data for both tumor models are shown in Supplementary Figs. S2 and S3. *, Significantly different from corresponding groups with P < 0.05; **, P < 0.01; or ***, P < 0.001. Color of asterisks indicates comparison groups as follows: red, to control; orange, combination to erlotinib; green, combination to alisertib, purple, alisertib to erlotinib. C, vehicle; E, erlotinib; A, alisertib; EA, erlotinib + alisertib.